Skip to main content

Table 4 Description of injectable regimens, toxicities and discontinuation among participants on MDR-TB treatment follow-up at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia

From: Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Characteristics N(%)
Type of injectable drug used
 Capreomycin 789 (84.7)
 Kanamycin 37 (5.6)
 Amikacin 40 (4.3)
 Streptomycin 2 (0.2)
Mean (± SD) duration on injectable treatment (months) 8.51 ± 2.3
Mean (± SD) total dose of injectables received(g) 158.5 ± 56.2
Switching of injectable 49 (5.3)
Discontinuation of injectable due to toxicity 34 (3.9)
 Hearing disturbance/ototoxicity 8 (0.9)
 Nephrotoxicity/clinical renal failure 26 (2.9)
Clinically diagnosed nephrotoxicity 62 (6.7)
Clinically diagnosed ototoxicity 42 (4.8)
 Hearing loss 16 (1.8)
 Imbalance 7 (0.8)
 Visual disturbance 19 (2.2)